Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerMarkers of resistance to anti-EGFR therapy in colorectal cancerMolecular origins of cancer: Molecular basis of colorectal cancerPhase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liverTreatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewEmerging molecular classifications and therapeutic implications for gastric cancerAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerMolecular testing to optimize therapeutic decision making in advanced colorectal cancerBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASPharmacologic resistance in colorectal cancer: a reviewNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialClinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancerBiomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancerAdjuvant chemotherapy for rectal cancer: Is it needed?Therapeutic strategy in unresectable metastatic colorectal cancer: an updated reviewA Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal CancerIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancerEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisMolecular profiling in the treatment of colorectal cancer: focus on regorafenibAssessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicineInfluence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analysesPersonalized treatment for advanced colorectal cancer: KRAS and beyondManagement of colorectal cancerFOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerMolecular alterations and biomarkers in colorectal cancerEGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysisTargeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicinePIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisCancer concepts and principles: primer for the interventional oncologist-part IINovel immunotherapeutic strategies of gastric cancer treatmentThe place of targeted agents in the treatment of elderly patients with metastatic colorectal cancerTargeting receptor tyrosine kinases in gastric cancerIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesReview of systemic therapies for locally advanced and metastatic rectal cancerAcquired resistance to EGFR-targeted therapies in colorectal cancerTreatment of metastatic colorectal cancer: focus on panitumumab
P2860
Q21142734-D0A3F111-1C8D-4498-9A84-10753E7425F6Q24563539-C97D65C6-20DF-456A-B4F6-E5E2F7511FEFQ24598640-36680113-71A3-46A1-AEF4-574A1C94FC2EQ24617331-EC370C8E-195B-4A6A-8902-D1C0CC551521Q24633957-EF166212-ACD5-4609-B52F-F70E0784C834Q26738801-FEF11391-F99E-4649-9446-D68F2091C981Q26740067-30843CB3-3DE4-46ED-A077-5F1B0F60EF41Q26745525-DA0A5DCD-2289-4DFB-9539-B2EF69996EFBQ26748924-C6F8D113-4988-4ACA-B60A-9997076A089CQ26749012-86CC1554-0DDA-40BF-8612-6FEEE5E21EB0Q26766535-74CCC7A4-507F-453F-B6A7-4084B21111F6Q26769850-95C85D23-F987-477D-8DC2-E32935A6C07FQ26769884-0C8F8AA2-4D83-4327-8648-88CE39A7C31DQ26769958-AF523678-FE50-49E0-831B-91BC3F9A0FC0Q26774605-6348FC4B-A486-426E-A193-4B7DE154E2F0Q26775099-2CF0DAF7-6D7D-4C00-BE79-BBCAB92DCC31Q26775522-33F0AD03-DB25-465E-BAD5-386774A1A29EQ26775711-28255677-EEBC-448D-97D8-1BE4EF26D924Q26775949-E3665CF9-D9BE-43DD-AFBC-34D83720B6CBQ26777704-A15D7D27-60A6-4E7C-ACA9-13B8DBC11124Q26778296-CF050E07-C96A-4AA9-A9D0-C0F909D5DF9BQ26783472-1C248AE4-8149-434F-BFF5-083087D43E96Q26786243-9E6870A7-7AD7-4011-AC28-5C26E149F7C8Q26822817-70E3B08C-779B-4BAB-9191-D86C4E46E4DEQ26823550-599BEE98-48FE-4D09-BB48-8A512F96B0D9Q26851060-47E106CB-3D4E-47E5-A29A-40661D94165AQ26852215-ED403FE1-9DE2-4DDD-835B-693F96CD33B9Q26862317-72055CDF-BDAD-4323-BBAD-F69EB30E2B63Q26865056-B73D42B8-BD16-4B14-8A6E-1D6FBC34C438Q26865436-EB42A152-702D-4A10-BDD9-3B41AB452E11Q26992267-4E8B361C-4053-4AE7-938F-47F9D071AFDDQ27010961-DAF7E299-8660-4F58-AF0C-DC86A1BCE735Q27011232-76DB23B6-68C1-4FD2-80A6-52E483739D6AQ27011366-E3AFF7C9-BD66-430A-87BE-131B03EDD3B3Q27013050-FF7F8E35-731C-4D94-872C-5FEE029A89C8Q27014174-6F9958EC-8A0B-4B83-A566-C1CB60324DB3Q27015224-50D906BF-9D2F-4B4D-B7CA-F4EDAA98F728Q27021105-5EB1B7B4-0B03-4F39-918F-5EB46D8C0338Q27022741-484F019D-9857-4758-9183-9F0D80F986B8Q27022954-1D1C4046-4B7B-408E-B178-E60FD59D8ED0
P2860
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Open-label phase III trial of ...... metastatic colorectal cancer.
@ast
Open-label phase III trial of ...... metastatic colorectal cancer.
@en
Open-label phase III trial of ...... metastatic colorectal cancer.
@nl
type
label
Open-label phase III trial of ...... metastatic colorectal cancer.
@ast
Open-label phase III trial of ...... metastatic colorectal cancer.
@en
Open-label phase III trial of ...... metastatic colorectal cancer.
@nl
prefLabel
Open-label phase III trial of ...... metastatic colorectal cancer.
@ast
Open-label phase III trial of ...... metastatic colorectal cancer.
@en
Open-label phase III trial of ...... metastatic colorectal cancer.
@nl
P2093
P50
P921
P3181
P356
P1476
Open-label phase III trial of ...... metastatic colorectal cancer.
@en
P2093
Alain Hendlisz
Bart Neyns
Gary Richardson
Jean-Luc Canon
Joan Maurel
Marc Peeters
Michael Wolf
Rafael G Amado
Yves Humblet
P304
P3181
P356
10.1200/JCO.2006.08.1620
P407
P577
2007-05-01T00:00:00Z